Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Show more

Location: Grafenauweg 8, Zug, 6300, Switzerland | Website: https://pharvaris.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

940M

52 Wk Range

$11.51 - $25.50

Previous Close

$17.25

Open

$17.60

Volume

10,150

Day Range

$17.24 - $18.10

Enterprise Value

723.3M

Cash

236.5M

Avg Qtr Burn

-33.59M

Insider Ownership

6.25%

Institutional Own.

89.49%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.